Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Beta-blocker drugs may improve survival time for melanoma patients

Beta-blocker drugs, commonly used to treat high blood pressure, may also play a major role in slowing the progression of certain serious cancers, based on a new study.

21 Sep 2011

New research has potential to alleviate side effects of cancer treatments

Beth Faiman MSN, CNP, a doctoral candidate at the Frances Payne Bolton School of Nursing at Case Western Reserve University, is studying whether an over-the-counter medication could ease chemotherapy side effects for people with blood and bone marrow cancers.

20 Sep 2011

Keryx completes enrollment in Zerenex Phase 3 long-term study for hyperphosphatemia

Keryx Biopharmaceuticals today announced completion of patient enrollment in the long-term study component of its Phase 3 registration program of Zerenex, the Company's ferric iron-based phosphate binder for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis.

20 Sep 2011

Positive data from Aeterna Zentaris' AEZS-108 Phase 2 study on advanced endometrial cancer

Aeterna Zentaris Inc. earlier today, presented positive final Phase 2 efficacy and safety data for its targeted cytotoxic luteinizing hormone releasing hormone (LHRH) analog, AEZS-108, in advanced endometrial cancer.

14 Sep 2011

Tensha raises $15 million in Series A financing to advance bromodomains for cancer

Tensha Therapeutics announced today that it has raised $15 million in a Series A financing to advance the development of small molecule bromodomain inhibitors for the treatment of cancer and other conditions by regulating the transcription of disease-associated genes.

12 Sep 2011

Scientists successfully disrupt function of MYC cancer gene

Dana-Farber Cancer Institute scientists have successfully disrupted the function of a cancer gene involved in the formation of most human tumors by tampering with the gene's "on" switch and growth signals, rather than targeting the gene itself.

12 Sep 2011

LC-MRM could provide better understanding of multiple myeloma drug resistance

12 Sep 2011

Moffitt researchers employ LC-MRM to detect acquired multiple myeloma drug resistance

"Acquired drug resistance" (ADR) is a major problem encountered in treating some forms of cancer. The ability to monitor the proteins involved in drug resistance has been a hurdle facing cancer researchers. However, a team of researchers at Moffitt Cancer Center, and colleagues, are pioneering promising research utilizing a monitoring technology that could provide a better understanding of ADR and assist in clinical decision-making for developing individualized patient treatments for multiple myeloma.

9 Sep 2011

9/11 firefighters at greater risk of cancer

A new study shows that firefighters who were exposed to toxic dust and fumes clogging the air after the World Trade Center towers collapsed 10 years ago are more likely to develop cancer.

2 Sep 2011

Favorable top-line results from Aeterna Zentaris' AEZS-130 Phase 3 study on AGHD

Aeterna Zentaris Inc. today announced favorable top-line results of its completed Phase 3 study with AEZS-130 as the first oral diagnostic test for Adult Growth Hormone Deficiency.

31 Aug 2011

Results of Aeterna Zentaris' AEZS-131 anticancer Erk inhibitor presented at ACS 2011 meeting

Aeterna Zentaris Inc. today announced that a poster on its novel orally active anticancer Erk inhibitor, which includes AEZS-131, was presented at the 242nd American Chemical Society National Meeting held at the Colorado Convention Center in Denver, Colorado.

30 Aug 2011

Patrys product shows activity in multiple myeloma cancer cells

Patrys Limited today announced the results of preclinical work conducted at The University Hospital of Würzburg showing the activity of one of Patrys’ products in multiple myeloma.

16 Aug 2011

Amorfix provides update on cancer therapeutic antibody programs

Amorfix Life Sciences Ltd., a product development company focused on diagnostics and therapeutics for misfolded protein diseases, provides an update on its cancer therapeutic antibody programs.

12 Aug 2011

NCI, Pharmacyclics sign CRADA to develop PCI-32765 for blood cancers

Pharmacyclics, Inc. today announced the signing of a five-year Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to collaborate on the development of PCI-32765, a first-in-class, small molecule inhibitor of Bruton's tyrosine kinase (Btk) for the treatment of hematologic malignancies.

10 Aug 2011

Criterium to manage Senesco's SNS01-T Phase Ib/2a multiple myeloma study

Senesco Technologies, Inc. today announced that it has contracted Criterium, Inc. to manage the operational aspects of its Phase Ib/2a clinical study of SNS01-T, the Company's lead therapeutic candidate for the treatment of multiple myeloma.

9 Aug 2011

Keryx reports net loss of $3.1 million for second quarter 2011

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease, today announced its results for the second quarter ended June 30, 2011.

8 Aug 2011

YM BioSciences reports preclinical results of CYT387 in multiple myeloma

YM BioSciences Inc., today reported preclinical results for its JAK1/JAK2 inhibitor CYT387 in multiple myeloma (MM), published in the advance online edition of Leukemia on July 26, 2011.

5 Aug 2011

ImmunoCellular receives new patent for ICT-69 to treat multiple myeloma, ovarian cancer

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, announced the issuance of a patent in France and the United Kingdom relating to the treatment and detection of multiple myeloma and ovarian cancer.

4 Aug 2011

ImmunoGen revenues increase to $19.3 million for fiscal year 2011

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today reported financial results for the three-month period and fiscal year ended June 30, 2011.

4 Aug 2011

Celgene reports second quarter total revenue of $1.18 billion

Celgene Corporation announced non-GAAP net income of $417 million, or non-GAAP diluted earnings per share of $0.89, for the quarter ended June 30, 2011. Non-GAAP net income for the second quarter of 2010 was $323 million, or non-GAAP diluted earnings per share of $0.69.

28 Jul 2011